TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
Cervera-Carrascon, V., Siurala, M., Santos, J. M., Havunen, R., Tähtinen, S., Karell, P., Sorsa, S., Kanerva, A., Hemminki, A.
Published in Oncoimmunology (04.05.2018)
Published in Oncoimmunology (04.05.2018)
Get full text
Journal Article
Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer
Quixabeira, D. C. A., Pakola, S., Jirovec, E., Havunen, R., Basnet, S., Santos, J. M., Kudling, T. V., Clubb, J. H. A., Haybout, L., Arias, V., Grönberg-Vähä-Koskela, S., Cervera-Carrascon, V., Kerkelä, E., Pasanen, A., Anttila, M., Tapper, J., Kanerva, A., Hemminki, A.
Published in Cancer gene therapy (01.12.2023)
Published in Cancer gene therapy (01.12.2023)
Get full text
Journal Article
Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine
Quixabeira, D. C. A., Jirovec, E., Pakola, S., Havunen, R., Basnet, S., Santos, J. M., Kudling, T. V., Clubb, J. H. A., Haybout, L., Arias, V., Grönberg-Vähä-Koskela, S., Cervera-Carrascon, V., Pasanen, A., Anttila, M., Tapper, J., Kanerva, A., Hemminki, A.
Published in Cancer gene therapy (01.11.2023)
Published in Cancer gene therapy (01.11.2023)
Get full text
Journal Article
1025P Fully intravenous delivery regimen of oncolytic adenovirus coding for TNFa and IL-2 (TILT-123) in patients with advanced solid cancers
Pakola, S.A., Jalkanen, K., Alanko, T.V., Clubb, J.H.A., Quixabeira, D.C.A., Jirovec, E., Kudling, T., Arias, V., Korpisaari, R., Jaakkola, M., Kononen, J.T., Sormunen, J., Pellinen, T., Haybout, L., Kistler, C., Sorsa, S., Havunen, R., Santos, J.M., Cervera-Carrascon, V., Hemminki, A.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1032TiP A phase I, first-in-human, study of TILT-123, a tumor-selective oncolytic adenovirus encoding TNFa and IL-2, in participants with advanced melanoma receiving adoptive T-cell therapy with tumor-infiltrating lymphocytes
Svane, I-M., Santos, J.M., Cervera-Carrascon, V., Havunen, R., Sorsa, S., Ellebæk, E., Monberg, T., Donia, M., Khammari, A., Dréno, B., Hemminki, A.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Revamping the ovarian tumour microenvironment with an oncolytic adenovirus yields enhanced tumour-infiltrating lymphocyte anti-tumour activity
Santos, J.M., Heiniö, C., Cervera-Carrascon, V., Siurala, M., Quixabeira, D.C.A., de Gruijl, T., Lassus, H., Kanerva, A., Hemminki, A.
Published in Annals of oncology (01.12.2019)
Published in Annals of oncology (01.12.2019)
Get full text
Journal Article
T-cell therapy: Enabling oncolytic adenoviruses for the treatment of melanoma
Santos, J.M., Siurala, M., Havunen, R., Cervera-Carrascon, V., Sorsa, S., Hemminki, A.
Published in Annals of oncology (01.12.2017)
Published in Annals of oncology (01.12.2017)
Get full text
Journal Article
Delivering complete responses against solid tumors by checkpoint blockade enabled with tumor necrosis factor alpha and interleukin-2 armed adenoviruses
Cervera-Carrascon, V., Santos, J.M., Siurala, M., Havunen, R., Sorsa, S., Hemminki, A.
Published in Annals of oncology (01.12.2017)
Published in Annals of oncology (01.12.2017)
Get full text
Journal Article
80P Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples
Basnet, S., Zafar, S., Launonen, I-M., Quixabeira, D.C.A., Santos, J., Hemminki, O., Malmstedt, M., Cervera-Carrascon, V., Aronen, P., Kalliokoski, R., Havunen, R., Rannikko, A., Mirtti, T., Matikainen, M., Kanerva, A., Hemminki, A.
Published in Annals of oncology (01.12.2020)
Published in Annals of oncology (01.12.2020)
Get full text
Journal Article
51P Immunological analysis of blood from patients with solid tumors treated with TILT-123: An oncolytic adenovirus encoding for tumor necrosis factor alpha (TNFa) and interleukin 2 (IL-2)
Pakola, S., Santos, J.M., Cervera-Carrascon, V., Kistler, C., Sorsa, S., Havunen, R., Hemminki, A.
Published in Immuno-oncology technology (01.12.2022)
Published in Immuno-oncology technology (01.12.2022)
Get full text
Journal Article
Replacing lymphodepleting preconditioning with an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin-2 in adoptive cell therapy
Santos, J.M., Cervera-Carrascon, V., Havunen, R., Zafar, S., Siurala, M., Sorsa, S., Anttila, M., Hemminki, A.
Published in Annals of oncology (01.12.2017)
Published in Annals of oncology (01.12.2017)
Get full text
Journal Article
Enhanced anti-cancer vaccines with a new epitope improvement system
Capasso, C., Magarkar, A., Cervera Carrascon, V., Müller, M., Garofalo, M., Kuryk, L., Fusciello, M., Ylösmäki, E., Bunker, A., Cerullo, V.
Published in Annals of oncology (01.11.2016)
Published in Annals of oncology (01.11.2016)
Get full text
Journal Article
Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma
Monberg, T.J., Kudling, T., Albieri, B., Pakola, S., Ellebaek, E., Donia, M., Eefsen, R.L., von Buchwald, C., Kistler, C., Santos, J.M., Clubb, J., Haybout, L., Westergaard, M.C.W., Quixabeira, D.C.A., Jirovec, E., Havunen, R., Sorsa, S., Cervera-Carrascon, V., Hemminki, A., Svane, I.M.
Published in Immuno-oncology technology (01.08.2024)
Published in Immuno-oncology technology (01.08.2024)
Get full text
Journal Article
52P MUC1 targeted immunotherapy with an oncolytic adenovirus coding for a bispecific T cell engager
Basnet, S., Santos, J.M., Quixabeira, D.C.A., Clubb, J., Grönberg-Vähä-Koskela, S., Pakola, S., Kudling, T., Heiniö, C., Havunen, R., Cervera-Carrascon, V., Sorsa, S., Anttila, M., Kanerva, A., Hemminki, A.
Published in Immuno-oncology technology (01.12.2022)
Published in Immuno-oncology technology (01.12.2022)
Get full text
Journal Article
50P Enhancing TIL and NK cells adoptive therapies with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer
Quixabeira, D.C.A., Pakola, S., Jirovec, E., Basnet, S., Santos, J.M., Kudling, T., Clubb, J., Haybout, L., Arias, V., Grönberg-Vähä-Koskela, S., Havunen, R., Cervera-Carrascon, V., Pasanen, A., Tapper, J., Kanerva, A., Hemminki, A.
Published in Immuno-oncology technology (01.12.2022)
Published in Immuno-oncology technology (01.12.2022)
Get full text
Journal Article
48O Safety and efficacy of combined treatment with tumor infiltrating lymphocytes (TILs) and oncolytic adenovirus TILT-123 for patients with metastatic melanoma: Results from a phase I trial
Monberg, T.J., Pakola, S., Dreno, B., Cervera-Carrascon, V., Ellebæk, E., Donia, M., Khammari, A., Kistler, C., Manuel Dos Santos, J., Clubb, J., Haybout, L., Albieri, B., Kudling, T., Quixabeira, D.C.A., Jirovec, E., Havunen, R., Juteau, S., Sorsa, S., Hemminki, A., Svane, I-M.
Published in Immuno-oncology technology (01.12.2023)
Published in Immuno-oncology technology (01.12.2023)
Get full text
Journal Article